TITLE: Glioblastoma Biomarker for Improved Survival Prediction
CASE NUMBER: C13155
UNMET NEED
Glioblastoma GBM), the most common primary brain tumor, has few available therapies providing significant improvement in survival. The median survival of patients after treatment is ~15 months, with only 3-5% surviving longer than 3 years. However, survival varies amongst GBM patients. Currently MGMT methylation status, IDH1 mutation status as well as GCIMP (Glioma CpGIsland Methylation Phenotype) are used as prognostic markers of long term survivorship but none are specific and sensitive enough to differentiate those patients that live for more that 3 years, underlying the need for better biomarkers of improved survival.
PROBLEM SOLVED
Dr. Lim and colleagues have demonstrated that:
1.The ZMIZ1 gene methylation status has proven to be more sensitive and specific in detecting long term survivors in glioblastoma.
2.ZMIZ1 can be useful in the prognosis of additional tumors including but not restricted to Advanced Ovarian CystadenoCa, Advanced Breast Ca, Lung Adenocarcinoma.
3.Identification of an alternative transcript of ZMIZ1 whose methylation is identified as a novel biomarker pf patient survival in glioblastoma.
4.Confirm the significance of the alternative transcript of ZMIZ1, in multiple other tumors including lower grade gliomas as well as other non-central nervous system tumors on a DNA methylation or RNA expression level.
STAGE OF DEVELOPMENT
•The invention is at the preclinical/discovery phase. The researchers performed epigenetic analysis of inter-tumoralheterogeneity in the TCGA glioblastoma cohort. They then validated the data obtained from the epigenetic analysis.
ASSOCIATED PUBLICATIONS
■Cancer Res August 1, 2015 75; 3839
PATENT STATUS: Pending
